His Plasma cell neoplasm research extends to the thematically linked field of Multiple myeloma. As part of his studies on Plasma cell neoplasm, he frequently links adjacent subjects like Plasmacytoma. Raymond Alexanian integrates Plasmacytoma and Myeloma protein in his studies. While working in this field, Raymond Alexanian studies both Myeloma protein and Multiple myeloma. Many of his studies on Internal medicine apply to Complete response as well. He conducted interdisciplinary study in his works that combined Chemotherapy and Clinical trial. As part of his studies on Gastroenterology, Raymond Alexanian frequently links adjacent subjects like Prednisone. Raymond Alexanian merges Surgery with Radiation therapy in his research. Raymond Alexanian merges many fields, such as Radiation therapy and Surgery, in his writings.
Part of his project on Cyclophosphamide includes research on Vincristine and ThioTEPA. Raymond Alexanian integrates many fields, such as Immunology, Antibody and Biochemistry, in his works. With his scientific publications, his incorporates both Biochemistry and Immunology. Raymond Alexanian performs multidisciplinary study on Multiple myeloma and ThioTEPA in his works. Internal medicine and Melphalan are commonly linked in his work. Raymond Alexanian merges many fields, such as Melphalan and Cyclophosphamide, in his writings. His multidisciplinary approach integrates Chemotherapy and Vincristine in his work. His study in Prednisone extends to Gastroenterology with its themes. His work in Prednisone is not limited to one particular discipline; it also encompasses Gastroenterology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson;Bart Barlogie;James Berenson;Seema Singhal.
The New England Journal of Medicine (2003)
International uniform response criteria for multiple myeloma
B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
S. Jagannath;B. Barlogie;J. Berenson;D. Siegel.
British Journal of Haematology (2004)
Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents
Bart Barlogie;Lon Smith;Raymond Alexanian.
The New England Journal of Medicine (1984)
Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
Donna M Weber;Kim Rankin;Maria Gavino;Kay Delasalle.
Journal of Clinical Oncology (2003)
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.
Raymond Alexanian;Arthur Haut;Asad U. Khan;Montague Lane.
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib
Paul G. Richardson;Hannah Briemberg;Sundar Jagannath;Patrick Y. Wen.
Journal of Clinical Oncology (2006)
Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma
Jordan U. Gutterman;George R. Blumenschein;Raymond Alexanian;Hwee-Yong Yap.
Annals of Internal Medicine (1980)
The Treatment of Multiple Myeloma
Raymond Alexanian;Meletios Dimopoulos.
The New England Journal of Medicine (1994)
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.
Jordan U. Gutterman;Seymour Fine;Jorge Quesada;Sandra J. Horning.
Annals of Internal Medicine (1982)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: